By Nana O 
In a groundbreaking clinical study, researchers from the Texas Biomedical Device Center (TxBDC) at The University of Texas at Dallas (UT Dallas) have reported unprecedented rates of recovery for individuals suffering from spinal cord injuries. This innovative therapy, which combines targeted vagus nerve stimulation with progressive, individualized rehabilitation, has demonstrated significant improvements in upper-limb function, offering a beacon of hope for a population with limited treatment options. The findings, published in the prestigious journal Nature on May 21, mark a critical advancement and pave the way for a pivotal trial aimed at seeking FDA approval.
A Novel Approach to Neuro-rehabilitation
The core of this revolutionary treatment lies in a technique dubbed closed-loop vagus nerve stimulation (CLV). This method involves the safe and precise stimulation of a nerve in the neck, synchronized with tailored rehabilitation exercises. Unlike previous interventions for spinal cord injury, where therapy alone often yields minimal gains, the CLV approach has shown remarkable efficacy in restoring lost function.
"In stroke, people who do only therapy may get better, and adding CLV multiplies that improvement," explained Dr. Michael Kilgard, the Margaret Fonde Jonsson Professor of Neuroscience at UT Dallas and the study’s corresponding author. "This study is different: Therapy alone for spinal cord injury didn’t help our participants at all. The vagus nerve stimulation was essential for unlocking recovery."
The therapy utilizes a miniature implanted device that delivers electrical pulses to the brain. These pulses are timed to coincide with specific rehabilitative movements, essentially reinforcing and enhancing the brain’s natural plasticity. This neuro-rehabilitation strategy builds upon over a decade of dedicated neuroscience and bioengineering research at UT Dallas, previously showing success in rewiring damaged brain areas in stroke survivors.
Clinical Trial Details and Remarkable Outcomes
The study, which served as both a Phase 1 and Phase 2 clinical trial, enrolled 19 participants with chronic, incomplete cervical spinal cord injuries. These individuals, ranging in age from 21 to 65, were one to 45 years post-injury. The rehabilitation program consisted of 12 weeks of intensive therapy, during which participants engaged in simple video games designed to elicit specific upper-limb movements. The vagus nerve stimulator was activated only when successful movements were performed, creating a feedback loop that facilitated neural adaptation.
The results were nothing short of remarkable. Participants experienced significant improvements in arm and hand strength, speed, range of motion, and overall hand function. These gains translate into tangible improvements in daily living activities, a critical factor for individuals with spinal cord injuries.
"These activities allow patients to regain strength, speed, range of motion and hand function. They simplify daily living," stated Dr. Robert Rennaker, Professor of Neuroscience and the Texas Instruments Distinguished Chair in Bioengineering, who was instrumental in designing the miniature implanted CLV device.
Crucially, the degree of improvement was not influenced by factors that often complicate treatment outcomes in other spinal cord injury therapies, such as age, time since injury, or the initial severity of impairment, provided there was some residual hand movement.
"This approach produces results regardless of these factors, which often cause significant differences in success rates of other types of treatment," emphasized Dr. Jane Wigginton, a medical doctor, Chief Medical Officer at TxBDC, co-director of UTD’s Clinical and Translational Research Center, and medical science research director at the Center for BrainHealth. Dr. Wigginton, who meticulously planned the clinical interactions and patient protection protocols for the trial, added, "It is remarkable from a medical standpoint."
A Decade of Progress Leading to This Breakthrough
The development of the CLV therapy for spinal cord injury is the culmination of a long-term research endeavor at TxBDC. Over the past 13 years, researchers have explored the potential of vagus nerve stimulation across a spectrum of neurological conditions. This extensive body of work has already led to FDA approval of vagus nerve stimulation for treating impaired upper-limb movement in stroke patients, demonstrating the technology’s established safety and efficacy in related neurological contexts.
The journey to this specific spinal cord injury breakthrough began with foundational research into neuroplasticity and the brain’s capacity for repair. Early studies, including those conducted by Dr. Seth Hays, Associate Professor of Bioengineering and a Fellow, Eugene McDermott Distinguished Professor in the Erik Jonsson School of Computer Science and Engineering, laid the groundwork. Dr. Hays has been involved with the CLV project since its inception.
"Prior to this study, no person with spinal cord injury had ever received CLV," Dr. Hays noted. "This is the first evidence that gains can be made. Now we will set about determining how we make this optimally effective."
The initial phase of the study incorporated a randomized placebo-controlled design. Nine of the 19 participants received sham stimulation for the first 18 therapy sessions, followed by active CLV treatment for the subsequent 18 sessions. This controlled approach helped validate the efficacy of the active stimulation compared to a non-therapeutic intervention.
Technological Advancements and Future Directions
The miniaturization of the implanted CLV device has been a significant factor in the program’s progression. The newest generation, designed by Dr. Rennaker, is approximately 50 times smaller than earlier versions, making the implantation procedure less invasive. Importantly, this advanced device is compatible with common medical imaging techniques such as MRIs, CT scans, and ultrasounds, which are often crucial for patient monitoring and care.
The success of this combined Phase 1/2 trial has propelled the research team toward a pivotal Phase 3 trial. This next stage, considered the final hurdle before seeking FDA approval for the treatment of upper-limb impairment due to spinal cord injury, will involve approximately 70 participants across multiple specialized spinal cord injury centers in the United States. The goal of this larger, multi-site trial is to further confirm the safety and efficacy of the CLV therapy in a broader patient population and under more diverse clinical conditions.
Broader Impact and Implications for Spinal Cord Injury Treatment
The implications of this research are profound, particularly for individuals living with spinal cord injuries, a condition that has historically presented formidable challenges for medical intervention. For many of these patients, the CLV therapy offers a tangible path to regaining abilities that were previously considered lost forever.
"The people in this study have now gained the ability to do things that are meaningful for them and impactful in their lives," stated Dr. Wigginton, highlighting the life-altering potential of this new treatment.
The research team acknowledges the long road ahead, emphasizing that even with promising results, regulatory and financial hurdles remain. "We still have a long road ahead. For many reasons — financial, regulatory or scientific — this could still die on the vine," cautioned Dr. Hays. "But we have positioned ourselves to succeed."
The collaborative nature of this research is also a key factor in its success. The TxBDC team acknowledged the indispensable contributions of their partners at Baylor University Medical Center, Baylor Scott & White Research Institute, and Baylor Scott & White Institute for Rehabilitation.
"This has been the hardest working, most altruistic group of professionals, and that has been incredibly impactful," said Dr. Wigginton, underscoring the dedication of all involved.
The commitment of the participants themselves has also been a critical element. Dr. Rennaker noted, "These patients said, ‘Put that device in me’ — that’s a huge commitment. They deserve credit for paving the path for others." This profound personal investment from the individuals who volunteered for the trial underscores the desperate need for effective treatments and their willingness to embrace novel approaches.
Funding and Future Prospects
The research was supported by significant funding, including a grant (N66001-17-2-4011) from the Defense Advanced Research Projects Agency (DARPA), an agency of the Department of Defense, and the Wings for Life Accelerated Translational Program. This diverse funding stream highlights the recognized importance and potential impact of this work.
The UT Dallas research team also includes several other key contributors: Joseph Epperson, TxBDC research associate; Emmanuel Adehunoluwa, cognition and neuroscience doctoral student; Amy Porter, TxBDC director of operations; Holle Carey Gallaway, TxBDC research biomedical engineer; and David Pruitt, who holds multiple degrees from UT Dallas.
It is important to note that Dr. Kilgard has a financial interest in MicroTransponder Inc., a company that markets vagus nerve stimulation therapy for stroke. Dr. Rennaker is the founder and CEO of XNerve, the company that developed the device utilized in this spinal cord injury study. These disclosures are standard practice in scientific reporting and are managed to ensure ethical conduct and transparency.
As the research progresses towards a Phase 3 trial, the scientific community and individuals affected by spinal cord injuries will be watching with keen interest. The potential for CLV to offer meaningful recovery where none previously existed represents a significant leap forward in the quest to restore function and improve the quality of life for those living with this challenging condition. The dedication of the researchers, the bravery of the participants, and the advancements in bioengineering have converged to create a truly unprecedented opportunity for healing and recovery.
